MTSR

Metsera, Inc. Common Stock
MTSR
Market cap $2.58B

24.51 USD

-2.71

9.96%

At close Apr 1, 4:00 PM EDT

1 day

-9.96%

5 days

-12.46%

1 month

-14.00%

3 months

-7.51%

6 months

-7.51%

Year to date

-7.51%

1 year

-7.51%

5 years

-7.51%

10 years

-7.51%

Healthcare Pharmaceutical Preparations

–

Funds holding %

of 7,398 funds

–

Analysts bullish %

Fund manager confidence

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$38

55%

upside

Avg. target

$47

92%

upside

High target

$56

128%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Guggenheim Seamus Fernandez 44% 1-year accuracy 8 / 18 met price target	128%upside $56	Buy Initiated	25 Feb 2025
B of A Securities Tim Anderson 43% 1-year accuracy 6 / 14 met price target	55%upside $38	Buy Initiated	25 Feb 2025

See Analyst Rankings

Financial journalist opinion

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, from 1:10 – 1:40 p.m. ET.

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing and a strong safety profile. Positive phase 2a results for MET-097i showed significant mean placebo-adjusted weight loss up to 11.3% without plateau after 12 weeks, with phase 2b and monthly dosing data expected in 2025. MET-233i, a long-acting amylin analog being explored in a phase 1 study, is expected to have a data release in mid-2025.

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

Why this newly public biotech could become a force in obesity treatments

Metsera's GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.

Why this newly public biotech could become a force in obesity treatments

This weight-loss drug stock could deliver a 90% return in 2025

Metsera Inc (NASDAQ: MTSR) has been pushing to the upside since its debut on Nasdaq on January 31st. But analysts are convinced the recent price action is a drop in the bucket compared to where this stock is headed in the long run.

This weight-loss drug stock could deliver a 90% return in 2025

24/7 Wall Street

Insider Buying Surges in February, Especially in These 6 Stocks

In January, the number of notable insider purchases was somewhat muted.

Insider Buying Surges in February, Especially in These 6 Stocks

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions, announced the closing of its initial public offering of 15,277,778 shares of its common stock, at an initial public offering price of $18.00 per share, on February 3, 2025. In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share, and the closing of the offering of such additional shares. All of the shares of common stock were offered by Metsera. The aggregate gross proceeds from the offering of the initial shares and the additional shares described above, before deducting underwriting discounts and commissions and other offering expenses, were $316.2 million. Metsera's common stock is listed on the Nasdaq Global Select Market under the ticker symbol “MTSR.”

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK Technology, and TV Channels Network. Two IPOs are currently scheduled for the week ahead, and a few more sizable names are eligible to launch.

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion.

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

Weight-loss drug developer Metsera raises $275 million in US IPO

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company said on Thursday.

Weight-loss drug developer Metsera raises $275 million in US IPO

See News Rankings

Charts implemented using Lightweight Charts™